Try Alerts Free   |   Login
Health Care › In Vitro And In Vivo Diagnostic Substances

OCX Price Correlated With Financials For Oncocyte

Free historical financial statements for Oncocyte Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 9 quarters since 2020. Compare with OCX stock chart to see long term trends.

OCX Stock Compared to Quarterly

OCX Income Statement

Revenue, Net:1424000
Revenue Per Share:0.012
Cost of Goods & Services Sold:1021000
Gross Profit:-533000
Selling, General & Admin Expense:5653000
Research & Development Expense:5128000
Total Operating Expenses:9362000
Operating Income:-10291000
Income Taxes:null
Net Income:-10291000
Earnings Per Share, Basic:-0.11
Shares Outstanding, Basic Avg:118513021

OCX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:287000
Change in Accounts Receiveable:685000
Net Cash from Operations:-13277000
Net Cash from Operations Per Share:-0.112
Net Cash from Financing Activities:-355000
Property, Plant & Equipment Purchases:1561000
Purchases of Businesses, Net of Cash:null
Net Cash from Investing Activities:-1561000
Net Change in Cash & Equivalents:-15193000

OCX Balance Sheet

Cash and Cash Equivalents:22112000
Accounts Receivable, Net:2122000
Total Current Assets:24623000
Property, Plant & Equipment, Net:7593000
Total Assets:146273000
Accounts Payable:2584000
Total Short-Term Liabilities:13955000
Total Liabilities:89306000

Insider Trading

SEC Form 4
5,931,707 sh at $1
5,931,707 sh at $1
6,003,752 sh at $1
Ross Douglas T.   Chief Scientific Officer
15,000 sh at $1
ANDREWS RONALD ASBURY   Chief Executive Officer
50,000 sh at $1
Paulsen Gisela   Chief Operating Officer
16,500 sh at $1
Redmond Cavan M.   Director
40,000 sh at $1
Levine Mitchell S   Chief Financial Officer
25,000 sh at $1
Organization, Description of the Business and Liquidity

Corporation (“Oncocyte”), incorporated in 2009 in the state of California, is a molecular diagnostics company focused on
developing and commercializing proprietary laboratory-developed tests (“LDTs”) to serve unmet medical needs across the cancer
care continuum. Oncocyte’s mission is to provide actionable information to physicians and patients at critical decision points
to optimize diagnosis and treatment decisions, improve patient outcomes, and reduce overall cost of care. Oncocyte has prioritized lung
cancer as its first indication. Lung cancer remains the leading cause of cancer death in the United States, despite the availability
of molecular testing and novel therapies to treat patients.

first product for commercial release is a proprietary treatment stratification test called DetermaRx™ that identifies which patients
with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate.
Beginning in September 2019 through February 23, 2021, Oncocyte held a 25 % equity interest in Razor Genomics, Inc. (“Razor”),
a privately held company, that has developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte
is commercializing as DetermaRx™. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding
shares of common stock of Razor and paid the selling shareholders in total $ 10 million in cash and issued them Oncocyte common stock
having a market value of $ 5.7 million on that date. As a result of the purchase of the Razor common stock, Oncocyte is now the sole shareholder
of Razor. The acquisition of the remaining equity interests has been accounted for as an asset acquisition in accordance with Accounting
Standards Codification (“ASC”) Topic 805-50, Business Combinations. See Note 3 for a full discussion of the Razor
asset acquisition.

completed its acquisition of Insight Genetics, Inc. (“Insight”) on January 31, 2020 (the “Insight Merger Date”)
through a merger with a newly incorporated wholly owned subsidiary of Oncocyte (the “Insight Merger”) under the terms of
an Agreement and Plan of Merger (the “Insight Merger Agreement”). Prior to the Insight Merger, Insight was a privately held
company specializing in the discovery and development of the multi-gene molecular, laboratory-developed diagnostic tests that Oncocyte
has branded as DetermaIO™. DetermaIO™ is a proprietary gene expression assay with promising data supporting its potential
to help identify patients likely to respond to checkpoint inhibitor drugs. Insight has a CLIA-certified diagnostic laboratory with the
capacity to support clinical trials or assay design on certain commercially available analytic platforms that may be used to develop
additional diagnostic tests. Insight also performs Pharma Services in its CLIA-certified laboratory for pharmaceutical and biotechnology
companies, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker
tests (“Pharma Services”). The Insight Merger has been accounted for using the acquisition method of accounting in accordance
with ASC 805, which requires, among other things, that the assets and liabilities assumed be recognized at their fair values as of the
acquisition date. See Note 3 for a full discussion of the Insight Merger.

April 15, 2021 (the “Chronix Merger Date”), Oncocyte completed its acquisition of Chronix Biomedical, Inc. (“Chronix”)
pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15,
2021 (as amended and restated, the “Chronix Merger Agreement”), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware
corporation and wholly-owned subsidiary of Oncocyte (“Merger Sub”), Chronix, the stockholders party to the Chro

Data imported from Oncocyte Corp SEC filings. Check original filings before making any investment decision.